Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, ...

Experts emphasized that obesity is a chronic, relapsing condition and lifelong therapy—in some form—will be necessary.

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...

Nausea is the most common tirzepatide side effect. In Zepbound clinical trials, 25 to 28 percent of people reported nausea. Tirzepatide might cause nausea because it ...

Tirzepatide can cost $500 to $1,900 a month without insurance. More affordable tirzepatide alternatives include semaglutide, ...

People taking weight-loss drugs are likely to regain the weight they have lost within two years of stopping the medications, ...